ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,037.88
      0.72%
      US Tech 100
      20,911.20
      0.90%
      Dow Jones
      44,556.04
      0.30%
      Brent Oil
      75.665
      -0.36%
      Bitcoin
      98,046.30
      0.19%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Immunocore Holdings PLC (IMCR) Quote

      Immunocore Holdings PLC

      Immunocore Holdings PLC (IMCR)

      NASDAQ
      30.76
      -0.41
      (-1.32%)
      Closed February 05 4:00PM
      Delayed by 15 minutes
      30.76
      -0.01
      (-0.03%)
      After Hours: 5:28PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      30.76
      Bid
      27.44
      Ask
      40.00
      Volume
      78,633
      30.74 Day's Range 31.94
      0.00 52 Week Range 0.00
      Market Cap
      1.479B
      Previous Close
      31.17
      Open
      31.18
      Last Trade
      2
      @
      32.23
      Last Trade Time
      Financial Volume
      $ 2,458,815
      VWAP
      31.2695
      Average Volume (3m)
      -
      Shares Outstanding
      48,088,346
      Dividend Yield
      -
      PE Ratio
      -26.76
      Earnings Per Share (EPS)
      -1.15
      Revenue
      249.43M
      Net Profit
      -55.29M

      About Immunocore Holdings PLC

      Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority o... Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States. Show more

      Sector
      Noncomml Resh Organizations
      Industry
      Noncomml Resh Organizations
      Website
      www.immunocore.com
      Headquarters
      Oxfordshire, Gbr
      Founded
      -
      Immunocore Holdings PLC is listed in the Noncomml Resh Organizations sector of the NASDAQ with ticker IMCR. The last closing price for Immunocore was $31.17. Over the last year, Immunocore shares have traded in a share price range of $ 0.00 to $ 0.00.

      Immunocore currently has 48,088,346 shares outstanding. The market capitalization of Immunocore is $1.50 billion. Immunocore has a price to earnings ratio (PE ratio) of -26.76.

      Ask ADVFN Intelligence (AI)

      IMCR Latest News

      More News

      Form 8-K - Current report

      January 10 2025
      Edgar (US Regulatory)

      Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

       Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma...

      January 10 2025
      GlobeNewswire Inc.

      Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

      Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc...

      January 06 2025
      GlobeNewswire Inc.

      Form 8-K - Current report

      January 02 2025
      Edgar (US Regulatory)

      Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

      Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...

      January 02 2025
      GlobeNewswire Inc.

      Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

      Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02...

      December 23 2024
      GlobeNewswire Inc.

      Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

      The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1...

      December 17 2024
      GlobeNewswire Inc.

      EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

      ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...

      December 11 2024
      GlobeNewswire Inc.

      Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

      Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England &...

      December 03 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      November 08 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      IMCR - Frequently Asked Questions (FAQ)

      What is the current Immunocore share price?
      The current share price of Immunocore is $ 30.76
      How many Immunocore shares are in issue?
      Immunocore has 48,088,346 shares in issue
      What is the market cap of Immunocore?
      The market capitalisation of Immunocore is USD 1.5B
      What is the 1 year trading range for Immunocore share price?
      Immunocore has traded in the range of $ 0.00 to $ 0.00 during the past year
      What is the PE ratio of Immunocore?
      The price to earnings ratio of Immunocore is -26.76
      What is the cash to sales ratio of Immunocore?
      The cash to sales ratio of Immunocore is 5.93
      What is the reporting currency for Immunocore?
      Immunocore reports financial results in USD
      What is the latest annual turnover for Immunocore?
      The latest annual turnover of Immunocore is USD 249.43M
      What is the latest annual profit for Immunocore?
      The latest annual profit of Immunocore is USD -55.29M
      What is the registered address of Immunocore?
      The registered address for Immunocore is 92 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, OX14 4RY
      What is the Immunocore website address?
      The website address for Immunocore is www.immunocore.com
      Which industry sector does Immunocore operate in?
      Immunocore operates in the NONCOMML RESH ORGANIZATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CAPTCaptiVision Inc
      $ 1.024
      (133.26%)
      		245.99M
      QNTMQuantum Biopharma Ltd
      $ 6.70
      (110.69%)
      		74.67M
      LTRYLottery com Inc
      $ 0.58
      (85.90%)
      		129.21M
      CPIXCumberland Pharmaceutical Inc
      $ 3.7801
      (77.47%)
      		18.29M
      INKTMiNK Therapeutics Inc
      $ 12.08
      (53.69%)
      		349.84k
      OMGAOmega Therapeutics Inc
      $ 0.1473
      (-69.25%)
      		11.43M
      VIRXViracta Therapeutics Inc
      $ 0.0352
      (-54.76%)
      		5.54M
      CYNCYNGN Inc
      $ 0.0708
      (-39.44%)
      		134.64M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2663
      (-36.20%)
      		1.8M
      CSAICloudastructure Inc
      $ 12.98
      (-31.68%)
      		53.38k
      NVDANVIDIA Corporation
      $ 118.65
      (1.71%)
      		247.88M
      CAPTCaptiVision Inc
      $ 1.024
      (133.26%)
      		245.99M
      PLTRPalantir Technologies Inc
      $ 103.83
      (23.99%)
      		212.8M
      RGTIRigetti Computing Inc
      $ 13.71
      (1.78%)
      		150.63M
      CYNCYNGN Inc
      $ 0.0708
      (-39.44%)
      		134.64M

      IMCR Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      IMCR under $40
      👍️0
      Monksdream Monksdream 5 months ago
      IMCR not looking so hot
      👍️0
      Monksdream Monksdream 10 months ago
      IMCR over $30
      👍️0

      Your Recent History

      NASDAQ
      IMCR
      Immunocore
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads